Pharmaceuticals News and Research

RSS

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

In the longest study of its kind, bariatric surgery has been shown to reduce the risk of heart attack and stroke in patients with diabetes. These results and other groundbreaking research were presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes, hosted by NewYork-Presbyterian Hospital and Weill Cornell Medical College.

31 Mar 2011

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Viewpoints: Vouchers for Medicare; evaluating the many parts of the health law; a single-payer plan for Oregon

With a hard deadline looming, talks to prevent a government shutdown have been stymied for a week because Tea Party members of the House have demanded everything: not just some of their cuts but almost all of them, and not just a reduction in spending but a reduction only in the programs they don't like. Many are insisting Democrats also agree to nonbudgetary riders, like ending the financing of Planned Parenthood or health care reform.

31 Mar 2011

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.

30 Mar 2011

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.

30 Mar 2011

AA Pharma launches Lithium Carbonate SR 300mg for Bipolar Disorder in Canada

AA Pharma Inc., a leading distributor of pharmaceuticals in Canada, is pleased to announce the launch of LITHMAX, a sustained release formulation containing 300mg of lithium carbonate. LITHMAX is indicated in the treatment of manic episodes of Bipolar Disorder, as well as the maintenance treatment for individuals with a diagnosis of Bipolar Disorder.

30 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

Columbia Labs' PROCHIEVE Phase III trial results to be published in online medical journal

Columbia Laboratories, Inc. today announced that the Company expects results from the PREGNANT Study, a Phase III clinical trial evaluating PROCHIEVE, will be published in a respected peer-reviewed medical journal online next week, and in the journal's print edition thereafter.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

WHO Director-General Margaret Chan on Monday responded to the first results of a probe into the agency's response to the H1N1 pandemic, Agence France-Presse reports.

30 Mar 2011

Unilife initiates Unifill syringe production for pharmaceutical companies

Unilife Corporation today announced it has commenced initial production of the Unifill ready-to-fill syringe at its FDA-registered manufacturing facility in York, Pennsylvania.

30 Mar 2011

Accelrys announces Modeling and Simulation Suite for optimizing R&D value chain

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the Accelrys Modeling and Simulation Suite, a pillar of the new Accelrys Enterprise R&D Architecture.

30 Mar 2011

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of patients with chronic hepatitis C.

30 Mar 2011

Valeant receives European Commission marketing authorization for Trobalt

Meda's partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.

30 Mar 2011

Cephalon receives unsolicited proposal from Valeant

Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.

30 Mar 2011

Pharmaceuticals News and Research

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Viewpoints: Vouchers for Medicare; evaluating the many parts of the health law; a single-payer plan for Oregon

Gilead and Yale enter multi-year cancer research collaboration

MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

AA Pharma launches Lithium Carbonate SR 300mg for Bipolar Disorder in Canada

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

BioSante completes patient enrollment in LibiGel Phase III trial against HSDD

DSP, Intercept enter license agreement for OCA

Columbia Labs' PROCHIEVE Phase III trial results to be published in online medical journal

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

Unilife initiates Unifill syringe production for pharmaceutical companies

Accelrys announces Modeling and Simulation Suite for optimizing R&D value chain

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Valeant receives European Commission marketing authorization for Trobalt

Cephalon receives unsolicited proposal from Valeant

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence